~~<i id='9484D5D86A'><strike id='9484D5D86A'><tt id='9484D5D86A'><pre id='9484D5D86A'></pre></tt></strike></i>~~

Home» Wikipedia» hotspot

hotspot

author：Wikipedia 2025-10-01 16:36:20 Page View：79521

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Arena BioWorks launches in Cambridge to speed drug discovery
Next article： Activists slam private health insurers over coverage restrictions

explore

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Arebiotech’sdogdaysover?What’saPIPE?AndwhatcanunseatWegovy?Wecoverallthatandmorethisweekon“TheReadou

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

FDA early review: GLP

SarahSilbiger/GettyImagesApreliminaryevaluationbytheFoodandDrugAdministrationdidnotfindevidencethatG